Efficacy and safety of antibody–drug conjugates in the treatment of urothelial cell carcinoma: a systematic review and meta-analysis of prospective clinical trials

Junwei Ren, Zeyu Chen, Yunjin Bai, Ping HanFrontiers in Pharmacology 2024 · DOI

TL;DR

This systematic review and meta-analysis of 12 prospective clinical trials (1,311 patients) confirms that antibody–drug conjugates (ADCs) are a highly effective "biological missile" for advanced urothelial carcinoma. With a pooled objective response rate of 40% and a disease control rate of 74%, ADCs offer a potent alternative for patients who have failed standard surgical or systemic interventions.

What Problem Does This Paper Address?

Urothelial carcinoma (UC) is the sixth most common cancer in developed nations and remains notoriously difficult to treat once it reaches advanced or metastatic stages. While surgical resection is the primary tool, it often fails to prevent recurrence or progression.

The emergence of Antibody–Drug Conjugates (ADCs)—which combine the precision of monoclonal antibodies with the cell-killing power of cytotoxic payloads—has shifted the landscape. However, because many ADC studies are early-phase or non-randomized, clinicians lack a consolidated, high-level view of their collective efficacy and safety. This paper synthesizes data from both randomized controlled trials (RCTs) and non-randomized studies (NRSIs) to provide a definitive look at how these drugs perform in the real world.

Methods

The authors conducted a systematic meta-analysis following PRISMA guidelines, searching major databases (PubMed, Embase, Cochrane, Web of Science) for studies published through September 2023.

Key technical aspects included: * Study Selection: Inclusion of 12 prospective trials covering four major ADCs: Enfortumab vedotin (EV), Sacituzumab govitecan (SG), Trastuzumab emtansine (TE), and Disitamab vedotin (DV). * Data Extraction: Beyond standard metrics, the team used the Engauge Digitizer tool to extract 6-month and 1-year survival rates directly from Kaplan–Meier curves. * Statistical Modeling: A random-effects model was used to account for the inherent heterogeneity between single-arm cohorts and RCTs. * Quality Assessment: RCTs were evaluated using the Risk of Bias (ROB) tool, while non-randomized cohorts were assessed via the Newcastle–Ottawa Scale (NOS).

Datasets

The "dataset" for this meta-analysis consisted of 12 prospective clinical studies involving a total of 1,311 patients.

  • ADCs Evaluated: Enfortumab vedotin (the most represented), Sacituzumab govitecan, Trastuzumab emtansine, and Disitamab vedotin.
  • Timeframe: Studies published between 2019 and 2023.
  • Patient Profile: Primarily patients with locally advanced or metastatic UC, many of whom were heavily pre-treated with chemotherapy or immunotherapy.

Key Insights and Ideas

  • The "Biological Missile" Success: The high Disease Control Rate (74%) compared to the Objective Response Rate (40%) suggests that ADCs are exceptionally good at stabilizing disease, even when they don't achieve a full "partial response" or "complete response" by RECIST criteria.
  • Dosage Matters: Subgroup analysis revealed that for Enfortumab vedotin (EV), a dosage of 1.25 mg/kg showed remarkably low heterogeneity in results, suggesting it may be the "sweet spot" for balancing efficacy and toxicity.
  • Heterogeneity Drivers: The authors found that most statistical variance (heterogeneity) stemmed from the type of ADC used and the specific dosage, rather than the study design (RCT vs. NRSI).
  • Manageable Toxicity: While 91% of patients experienced some form of treatment-related adverse event (TRAE), the rate of fatal TRAEs was only 1%. This suggests that while the side effects are frequent, they are rarely life-threatening in a clinical setting.

Key Results

  • Tumor Response: Pooled Objective Response Rate (ORR) was 40%; Pooled Disease Control Rate (DCR) was 74%.
  • Survival:
    • Median Progression-Free Survival (PFS): 5.66 months.
  • Median Overall Survival (OS): 12.63 months.
  • 1-year OS rate: 55%.
  • Safety Profile: The most common side effects were Alopecia (45%), Nausea (45%), Fatigue (39%), and Peripheral Sensory Neuropathy (37%). Grade III or higher (severe) adverse events occurred in approximately 49% of the pooled population.

Limitations and Future Work

The authors acknowledge several constraints:

  1. Small RCT Sample: Only five of the twelve studies were randomized controlled trials, which limits the ability to compare ADCs directly against standard-of-care treatments.
  2. Single-Arm Bias: Many included studies were single-arm, which can introduce selection bias.
  3. Treatment History: Most patients were heavily pre-treated. The efficacy of ADCs as a first-line (frontline) therapy is still being explored (e.g., the EV-302 trial).
  4. Future Directions: The paper suggests that the next frontier is combination therapy, particularly pairing ADCs with immune checkpoint inhibitors (ICIs) like pembrolizumab, which has already shown synergistic potential in recent trials.

Summary updated

Abstract

<b>Introduction:</b> Urothelial carcinoma (UC) is a refractory disease for which achieving satisfactory outcomes remains challenging with current surgical interventions. Antibody-drug conjugates (ADCs) are a novel class of targeted therapeutics that have demonstrated encouraging results for UC. Although there is a limited number of high-quality randomized control trials (RCTs) examining the use of ADCs in patients with UC, some prospective non-randomized studies of interventions (NRSIs) provide valuable insights and pertinent information. We aim to assess the efficacy and safety of ADCs in patients with UC, particularly those with locally advanced and metastatic diseases. <b>Methods:</b> A systematic search was conducted across PubMed, Embase, the Cochrane Library, and Web of Science databases to identify pertinent studies. Outcomes, such as the overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), adverse events (AEs), and treatment-related adverse events (TRAEs), were extracted for further analyses. <b>Results:</b> Twelve studies involving 1,311 patients were included in this meta-analysis. In terms of tumor responses, the pooled ORR and DCR were 40% and 74%, respectively. Regarding survival analysis, the pooled median PFS and OS were 5.66 months and 12.63 months, respectively. The pooled 6-month PFS and OS were 47% and 80%, while the pooled 1-year PFS and OS were 22% and 55%, respectively. The most common TRAEs of the ADCs were alopecia (all grades: 45%, grades ≥ III: 0%), decreased appetite (all grades: 34%, grades ≥ III: 3%), dysgeusia (all grades: 40%, grades ≥ III: 0%), fatigue (all grades: 39%, grades ≥ III: 5%), nausea (all grades: 45%, grades ≥ III: 2%), peripheral sensory neuropathy (all grades: 37%, grades ≥ III: 2%), and pruritus (all grades: 32%, grades ≥ III: 1%). <b>Conclusion:</b> The meta-analysis in this study demonstrates that ADCs have promising efficacies and safety for patients with advanced or metastatic UC. <b>Systematic review registration:</b> https://www.crd.york.ac.uk/prospero/, identifier: CRD42023460232.
BibTeX
@inproceedings{ren2024efficacy,
  author = {Junwei Ren and Zeyu Chen and Yunjin Bai and Ping Han},
  title = {{Efficacy and safety of antibody–drug conjugates in the treatment of urothelial cell carcinoma: a systematic review and meta-analysis of prospective clinical trials}},
  booktitle = {Frontiers in Pharmacology},
  year = {2024},
  doi = {10.3389/fphar.2024.1377924},
}
Figure